Published in Prostate on February 15, 2004
Characterization of prostate cancer detected at repeat biopsy. BMC Urol (2008) 0.83
Detection rate of clinically insignificant prostate cancer increases with repeat prostate biopsies. Asian J Androl (2012) 0.81
Clinicopathologic differences between prostate cancers detected during initial and repeat transrectal ultrasound-guided biopsy in Korea. Korean J Urol (2014) 0.75
Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol (2007) 9.67
Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores. J Urol (2004) 3.15
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
Robotic-assisted laparoscopic partial nephrectomy: technique and initial clinical experience with DaVinci robotic system. Urology (2004) 2.68
Gender-related fetal development of the internal urethral sphincter. Urology (2013) 2.61
Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int (2008) 2.60
Adult stem cell therapy of female stress urinary incontinence. Eur Urol (2007) 2.48
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol (2010) 2.47
Comparison of contrast enhanced color Doppler targeted biopsy with conventional systematic biopsy: impact on prostate cancer detection. J Urol (2002) 2.37
Retracted Autologous myoblasts and fibroblasts versus collagen for treatment of stress urinary incontinence in women: a randomised controlled trial. Lancet (2007) 2.35
Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. Proc Natl Acad Sci U S A (2009) 2.33
Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol (2008) 2.32
Total reconstruction of the vesico-urethral junction. BJU Int (2008) 2.28
Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med Genomics (2011) 2.24
Optimizing the outcome of microsurgical subinguinal varicocelectomy using isosulfan blue: a prospective randomized trial. J Urol (2006) 2.15
Combination of lidocaine suppository and periprostatic nerve block during transrectal prostate biopsy: a prospective randomized trial. Int J Urol (2014) 1.98
Up-regulation of neutrophil gelatinase-associated lipocalin in colorectal cancer predicts poor patient survival. World J Surg (2014) 1.98
Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth Analg (2009) 1.95
Early diagnosis and straight forward surgery of an asymptomatic primary angiosarcoma of the kidney led to long-term survival. Int J Urol (2006) 1.92
Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: assessment using colour Doppler ultrasonography. BJU Int (2008) 1.83
Anderson-Hynes dismembered pyeloplasty performed using the da Vinci robotic system. Urology (2002) 1.81
Evaluation of the PI-RADS scoring system for mpMRI of the prostate: a whole-mount step-section analysis. World J Urol (2014) 1.78
Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem (2005) 1.73
Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer. Urology (2007) 1.69
Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate (2005) 1.68
Robotic-assisted laparoscopic partial nephrectomy: surgical technique and clinical outcomes at 1 year. BJU Int (2008) 1.68
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol (2008) 1.68
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol (2003) 1.67
Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol (2005) 1.67
Robotic Anderson-Hynes pyeloplasty: 5-year experience of one centre. BJU Int (2007) 1.67
Somatic mutations throughout the entire mitochondrial genome are associated with elevated PSA levels in prostate cancer patients. Am J Hum Genet (2010) 1.67
TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol (2007) 1.63
Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res (2005) 1.62
Diagnostic accuracy of guided cervical biopsies: a prospective multicenter study comparing the histopathology of simultaneous biopsy and cone specimen. Am J Obstet Gynecol (2010) 1.60
Early results of bladder-cancer screening in a high-risk population of heavy smokers. BJU Int (2008) 1.58
Histologic pathologies of the myocardium in septic shock: a prospective observational study. Shock (2013) 1.55
Autologous myoblasts and fibroblasts for female stress incontinence: a 1-year follow-up in 123 patients. BJU Int (2007) 1.55
Safer transurethral resection of the prostate: coagulating intermittent cutting reduces hemostatic complications. J Urol (2004) 1.54
Intensifying the saturation biopsy technique for detecting prostate cancer after previous negative biopsies: a step in the wrong direction. BJU Int (2008) 1.52
Publication output in telemedicine during the period January 1964 to July 2003. J Telemed Telecare (2004) 1.51
Androgen axis in prostate cancer. J Cell Biochem (2006) 1.48
Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol (2012) 1.48
Different types of atrophy in the prostate with and without adenocarcinoma. Eur Urol (2006) 1.48
Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology (2003) 1.46
Real-time elastography for detecting prostate cancer: preliminary experience. BJU Int (2007) 1.44
Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol (2004) 1.44
Giant cystine stone in an infant bladder with no evidence of cystinuria--valence of possible pathomechanisms. Urol Int (2005) 1.44
Endoscopic application of dextranomer/hyaluronic acid copolymer in the treatment of vesico-ureteric reflux after renal transplantation. BJU Int (2010) 1.44
Functional and histological changes after myoblast injections in the porcine rhabdosphincter. Eur Urol (2007) 1.43
Blunt renal trauma in children: 26 years clinical experience in an alpine region. Eur Urol (2002) 1.42
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2011) 1.42
Influence of nitrate levels in drinking water on urological malignancies: a community-based cohort study. BJU Int (2005) 1.41
Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol (2003) 1.40
Remitting seronegative syndrome with pitting edema as the presenting symptom in a young, male patient with sarcoidosis: a case report. Arthritis Rheum (2008) 1.38
Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res (2002) 1.37
hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. Cancer Res (2006) 1.33
The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis. J Exp Ther Oncol (2004) 1.32
Late penile metastasis from primary bladder carcinoma. Urology (2003) 1.32
Cancer of the prostate. Crit Rev Oncol Hematol (2005) 1.31
Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol (2004) 1.31
Amniotic fluid and placental stem cells. Methods Enzymol (2006) 1.30
Plexin-B1 mutations in prostate cancer. Proc Natl Acad Sci U S A (2007) 1.28
Factors contributing to the racial differences in prostate cancer mortality. BJU Int (2005) 1.26
The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer. J Mol Med (Berl) (2012) 1.23